RELMADA THERAPEUTICS RLMD 深 沪
已收盘 08-21 16:00:00 美东时间
4.63
-0.010
-0.22%
华盛通- 最 高4.76
- 今 开4.68
- 成交量 98.52万股
- 最 低 4.54
- 昨 收 4.64
- 总市值 4.94亿
- 52周最高 8.00
- 市盈率 静 --
- 换手率 0.92%
- 52周最低 1.06
- 委 比 -83.67%
- 总股本 1.07亿
- 历史最高 54.00
- 量 比 1.16
- 振 幅 4.74%
- 历史最低 0.2404
- 每 手 1
- 风险率 1.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Relmada Therapeutics Joins Russell 2000 Index And The Russell 3000 Index Effective
Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company"))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after...
06-29 19:08
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
On Thursday, HC Wainwright initiated coverage on Relmada Therapeutics Inc. (NASDAQ:RLMD) with a primary focus on bladder cancer treatment regimen. The clinical-stage biotechnology company is focused on developing therapies for oncology and central nervous system conditions, with NDV-01 and sepranolo...
06-19 01:38
HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $12.
06-18 18:06
Relmada Therapeutics Increases Authorized Common Stock From 150M To 200M Shares Following Shareholder Approval
On May 28, 2026, Relmada Therapeutics, Inc. (the "Company") filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to increase the number of authorized
05-29 05:24
Relmada Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed
RELMADA THERAPEUTICS, INC.COMMON STOCKPREFERRED STOCKWARRANTSSUBSCRIPTION RIGHTSDEPOSITARY SHARESPURCHASE CONTRACTSUNITSThis prospectus relates to common stock, preferred stock, warrants, subscription rights, depositary
05-14 04:56
Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call
On Tuesday, Relmada Therapeutics (NASDAQ:RLMD) discussed first-quarter financia...
05-13 05:11
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19
Mizuho analyst Uy Ear maintains Relmada Therapeutics (NASDAQ:RLMD) with a Outperform and raises the price target from $10 to $19.
03-20 21:44
